US Patent 9682013 Pharmaceutical compositions comprising human antibodies to PCSK9
Patent 9682013 was granted and assigned to Sanofi on June, 2017 by the United States Patent and Trademark Office.
All edits
The present invention relates to Pharmaceutical compositions comprising an antibody specifically binding to human proprotein convertase subtilisin/kexin type 9 (PCSK9), to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact.
US Patent 09682013 Pharmaceutical compositions comprising human antibodies to PCSK9 US Patent 9682013 Pharmaceutical compositions comprising human antibodies to PCSK9
US Patent 09682013 Pharmaceutical compositions comprising human antibodies to PCSK9
Find more entities like US Patent 9682013 Pharmaceutical compositions comprising human antibodies to PCSK9
